Paper Details

  1. Home
  2. Paper Details

Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.

Author: AoyamaH, DoiharaH, KimuraM, KomakiK, KusamaM, MitsuyamaS, MiyauchiK, SanoM

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Toremifene (TOR) is more effective than tamoxifen (TAM) in improving serum lipid levels in patients with hormone receptor-positive breast cancer. After 12 months of treatment, TOR significantly increased HDL-C levels and decreased TG levels compared to TAM.
Paper Details　
Original Abstract of the Article :
This study clarified the difference in the effects on serum lipids between toremifene (TOR) and tamoxifen (TAM). To remove influencing factors, we investigated adjuvant therapy for hormone receptor-positive patients with breast cancer without lymph node metastasis. The subjects were 65 patients who ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s10549-004-4384-z

データ提供：米国国立医学図書館（NLM）

Hormone Receptor-Positive Breast Cancer: A Tale of Two SERMs

The world of breast cancer treatment is a vast desert, and researchers are constantly searching for new oases of hope. This study delves into the fascinating world of selective estrogen receptor modulators (SERMs), specifically toremifene (TOR) and tamoxifen (TAM). The researchers wanted to understand how these drugs affect lipid levels in postmenopausal women with hormone receptor-positive breast cancer, a type of cancer that thrives on estrogen. They conducted a randomized comparative study with 65 women, administering either 20 mg of TAM or 40 mg of TOR for a year. The researchers measured a variety of lipid levels before and after treatment, and what they discovered was a fascinating difference between the two SERMs.

TOR emerges as a potential winner

The results showed that both TOR and TAM effectively lowered total cholesterol, LDL-C, Lp(a), and Apo B. However, TOR stood out by increasing HDL-C, the good cholesterol, while TAM did not. Additionally, TOR effectively reduced triglycerides (TG) after 12 months, while TAM led to an increase. This difference in lipid metabolism suggests that TOR might offer a more favorable lipid profile compared to TAM.

Keeping the Desert of Estrogen in Check

This study has important implications for understanding the effects of SERMs on lipid metabolism. It emphasizes the need for individualized treatment approaches, considering factors like a patient's lipid profile and overall health. This research can guide physicians in selecting the most suitable SERM for individual patients. It's like choosing the right camel to navigate the vast desert of treatment options!

Dr.Camel's Conclusion

This research reminds us that there's no one-size-fits-all solution in medicine. The study's findings about the different effects of TOR and TAM on lipid profiles highlight the importance of personalized approaches to cancer treatment. Just like a skilled traveler adapts their camel to the specific challenges of the desert, healthcare professionals must carefully consider each patient's needs and choose the most effective treatment option.

Date :
  1. Date Completed 2005-02-25
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

15538040

DOI: Digital Object Identifier

10.1007/s10549-004-4384-z

Related Literature

Article Analysis
・Effects of toremifene
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.